Today: 21 May 2026
Browse Category

NASDAQ:LIF 8 December 2025 - 25 January 2026

Why Life360 stock is sliding today as year-end trading hits tech names

Why Life360 stock is sliding today as year-end trading hits tech names

Life360 shares fell 4.4% to $63.79 in morning Nasdaq trading, down $2.94 from Tuesday’s close, with about 108,000 shares changing hands. The drop came as tech stocks extended losses on the final trading day of 2025. Life360 recently raised its full-year revenue outlook and agreed to buy ad-tech firm Nativo for $120 million. The company’s next earnings report is set for Feb. 26.
31 December 2025
···
Life360 Stock (NASDAQ: LIF) Slides on Dec. 17, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching Next

Life360 Stock (NASDAQ: LIF) Slides on Dec. 17, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching Next

Life360 shares fell 8.6% to $58.75 on Dec. 17, closing near session lows after opening above $64. The drop came without a new company announcement, amid below-average trading volume and recent shifts in analyst ratings. UBS cut its price target to $110, while DA Davidson initiated coverage at $94. Life360’s average 12-month target stands at $93.63, with a low estimate of $58.
17 December 2025
···
Life360 (ASX:360, Nasdaq:LIF) Stock on 8 December 2025: Q3 Beat, Nativo Deal, Sell‑Off and 2026 Forecasts

Life360 (ASX:360, Nasdaq:LIF) Stock on 8 December 2025: Q3 Beat, Nativo Deal, Sell‑Off and 2026 Forecasts

Life360 shares closed at A$37.83 on the ASX, down 3.84% and among the index’s biggest losers on 8 December, despite reporting record Q3 results and a major ad-tech acquisition. The Nasdaq line traded around US$73.18, with intraday swings between US$71.90 and US$78.01. Technical models project further downside, labeling the stock a “sell candidate” despite recent growth.
8 December 2025
··

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop